432 related articles for article (PubMed ID: 18988205)
1. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
2. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
3. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
[TBL] [Abstract][Full Text] [Related]
4. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
5. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
6. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
7. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
8. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
9. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
10. Computational investigations of hERG channel blockers: New insights and current predictive models.
Villoutreix BO; Taboureau O
Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
[TBL] [Abstract][Full Text] [Related]
11. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500
[TBL] [Abstract][Full Text] [Related]
13. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
14. Predictive models for HERG channel blockers: ligand-based and structure-based approaches.
Thai KM; Ecker GF
Curr Med Chem; 2007; 14(28):3003-26. PubMed ID: 18220737
[TBL] [Abstract][Full Text] [Related]
15. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
16. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
Zünkler BJ
Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
[TBL] [Abstract][Full Text] [Related]
17. Effects of common antitussive drugs on the hERG potassium channel current.
Deisemann H; Ahrens N; Schlobohm I; Kirchhoff C; Netzer R; Möller C
J Cardiovasc Pharmacol; 2008 Dec; 52(6):494-9. PubMed ID: 19034038
[TBL] [Abstract][Full Text] [Related]
18. hERG: protein trafficking and potential for therapy and drug side effects.
Staudacher I; Schweizer PA; Katus HA; Thomas D
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
[TBL] [Abstract][Full Text] [Related]
19. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Gintant GA; Su Z; Martin RL; Cox BF
Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
[TBL] [Abstract][Full Text] [Related]
20. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]